New York, NY, United States of America

Javier Pinilla-Ibarz

USPTO Granted Patents = 6 


 

Average Co-Inventor Count = 2.6

ph-index = 5

Forward Citations = 85(Granted Patents)


Location History:

  • New York, NY (US) (2009 - 2014)
  • Tampa, FL (US) (2016 - 2023)

Company Filing History:


Years Active: 2009-2023

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovations of Javier Pinilla-Ibarz

Introduction

Javier Pinilla-Ibarz is a notable inventor based in New York, NY, who has made significant contributions to the field of cancer research. With a total of six patents to his name, he has focused on developing innovative methods for treating cancers that express the WT1 antigen. His work is pivotal in advancing therapeutic strategies for patients suffering from these types of cancers.

Latest Patents

Among his latest patents is the invention titled "WT1 HLA class II-binding peptides and compositions and methods comprising same." This invention provides WT1 peptides and outlines methods for treating, reducing the incidence of, and inducing immune responses against WT1-expressing cancers. The significance of this invention lies in its potential to improve treatment outcomes for patients with specific cancer types.

Career Highlights

Javier has worked with prestigious institutions such as the Sloan Kettering Institute for Cancer Research and Memorial Sloan Kettering Cancer Center. His experience in these leading research organizations has allowed him to collaborate with some of the brightest minds in the field of oncology.

Collaborations

Some of his notable coworkers include David A. Scheinberg and Rena May, who have also contributed to advancements in cancer research. Their collaborative efforts have further enhanced the impact of their work in the medical community.

Conclusion

Javier Pinilla-Ibarz's contributions to cancer research through his innovative patents and collaborations highlight his commitment to improving patient care. His work continues to inspire advancements in the treatment of WT1-expressing cancers.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…